Compare QD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QD | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.5M | 942.6M |
| IPO Year | 2017 | 2019 |
| Metric | QD | PHAT |
|---|---|---|
| Price | $3.84 | $14.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 310.9K | ★ 809.7K |
| Earning Date | 11-24-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2364.38 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | $12,647,260.00 | ★ $147,190,000.00 |
| Revenue This Year | N/A | $218.59 |
| Revenue Next Year | N/A | $84.38 |
| P/E Ratio | $6.13 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $2.04 | $2.21 |
| 52 Week High | $5.08 | $16.45 |
| Indicator | QD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 31.11 | 52.94 |
| Support Level | $3.89 | $14.12 |
| Resistance Level | $4.91 | $16.45 |
| Average True Range (ATR) | 0.18 | 0.74 |
| MACD | -0.11 | -0.11 |
| Stochastic Oscillator | 1.83 | 21.46 |
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.